Cargando…
Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies
RATIONALE & OBJECTIVE: Chronic kidney disease–associated pruritus (CKD-aP) in patients treated by hemodialysis (HD) impairs quality of life (QoL). Difelikefalin, a selective κ-opioid receptor agonist, decreased the intensity of CKD-aP in patients undergoing HD. This pooled analysis evaluated dif...
Autores principales: | Topf, Joel, Wooldridge, Thomas, McCafferty, Kieran, Schömig, Michael, Csiky, Botond, Zwiech, Rafal, Wen, Warren, Bhaduri, Sarbani, Munera, Catherine, Lin, Rong, Jebara, Alia, Cirulli, Joshua, Menzaghi, Frédérique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396406/ https://www.ncbi.nlm.nih.gov/pubmed/36016762 http://dx.doi.org/10.1016/j.xkme.2022.100512 |
Ejemplares similares
-
Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients
por: Fishbane, Steven, et al.
Publicado: (2020) -
Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program
por: Fishbane, Steven, et al.
Publicado: (2022) -
Safety and Effectiveness of Difelikefalin in Patients With Moderate-to-Severe Pruritus Undergoing Hemodialysis: An Open-Label, Multicenter Study
por: Weiner, Daniel E., et al.
Publicado: (2022) -
Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis
por: Stark, Jeffrey G., et al.
Publicado: (2023) -
Assessment of the physical dependence potential of difelikefalin: Randomized placebo‐controlled study in patients receiving hemodialysis
por: Spencer, Robert H., et al.
Publicado: (2023)